Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Domatinostat + Sirolimus |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Domatinostat | 4SC-202 | HDAC Inhibitor 45 | Domatinostat (4SC-202) is a class I histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cells (PMID: 26773495, PMID: 30347469, PMID: 32210076). | |
| Sirolimus | Rapamune | Rapamycin | mTORC1 Inhibitor 9 | Rapamune (sirolimus) binds to the FKBP-12 to generate an immunosuppressive complex that binds and allosterically inhibits mTOR (PMID: 25261369). Rapamune (sirolimus) is FDA approved for the prevention of renal transplant rejection and for patients with lymphangioleiomyomatosis (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07725380 | Phase Ib/II | Domatinostat + Sirolimus | Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma | Recruiting | USA | 0 |